GAMMA Investing LLC Boosts Stake in Merck & Co., Inc. $MRK

GAMMA Investing LLC increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 6.4% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 94,992 shares of the company’s stock after acquiring an additional 5,736 shares during the period. GAMMA Investing LLC’s holdings in Merck & Co., Inc. were worth $12,207,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Norges Bank purchased a new position in Merck & Co., Inc. during the fourth quarter worth approximately $3,997,933,000. Wellington Management Group LLP increased its position in shares of Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company’s stock valued at $9,098,196,000 after buying an additional 11,156,354 shares in the last quarter. Cardano Risk Management B.V. acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $1,012,530,000. Jennison Associates LLC acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth approximately $585,192,000. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Merck & Co., Inc. by 37.9% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 18,753,390 shares of the company’s stock worth $1,973,983,000 after buying an additional 5,152,069 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. Adjusted loss per share of $0.13 was also better than the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth engine, while the newer injectable version of the cancer treatment exceeded Wall Street expectations by more than $200 million. Strength in oncology and other newer products helped support the improved sales outlook. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised and narrowed its full-year 2026 revenue forecast to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion analyst consensus. Management also highlighted regulatory, clinical and pipeline milestones that could support longer-term growth. MRK Q2 Earnings and Sales Beat Estimates, 2026 Sales View Raised
• Negative Sentiment: Merck cut its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus estimate, because of charges associated with the acquisition of Terns Pharmaceuticals. The resulting earnings pressure offsets part of the benefit from the stronger sales outlook. Merck hikes revenue outlook but cuts profit guidance due to deal charges

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $128.28 on Wednesday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. The stock’s 50 day simple moving average is $123.45 and its 200-day simple moving average is $118.78. The company has a market cap of $316.83 billion, a PE ratio of 36.14, a price-to-earnings-growth ratio of 5.07 and a beta of 0.19. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.05.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm had revenue of $16.61 billion during the quarter, compared to analysts’ expectations of $16.37 billion. During the same period in the previous year, the business earned $2.13 earnings per share. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities research analysts anticipate that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is 95.77%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. UBS Group lifted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, April 13th. JPMorgan Chase & Co. upped their price objective on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Wells Fargo & Company increased their price objective on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. BMO Capital Markets lifted their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Citigroup began coverage on shares of Merck & Co., Inc. in a research note on Wednesday, May 6th. They set a “neutral” rating and a $125.00 target price for the company. Thirteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $134.50.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.